Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

602
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
602
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

22
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

19
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

22
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Angina IV: Management01:26

Angina IV: Management

15
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
15
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 1.

Korean circulation journal·2026
Same author

Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 2.

Korean circulation journal·2026
Same author

Contemporary Clinical Practices in Korean Patients With Coronary Chronic Total Occlusion: Results From the K-CTO Nationwide Retrospective Registry.

Korean circulation journal·2026
Same author

Contemporary CTO Management in Korea: Insights from the K-CTO Registry 2.0.

Korean circulation journal·2026
Same author

Beyond the Binary: Refining Dual Antiplatelet Therapy With the PRECISE-HBR Score.

JACC. Cardiovascular interventions·2026
Same author

Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease.

Journal of the American Heart Association·2026

相关实验视频

Updated: Aug 22, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

通过皮肤进行冠状动脉干预后使用阿司匹林与克洛皮多格勒进行长期维持单一治疗:HOST-EXAM扩展研究

Jeehoon Kang1, Kyung Woo Park1, Huijin Lee1

  • 1Seoul National University Hospital, Korea (J.K., K.W.P., H.L., D.H., H.-M.Y., J.-K.H., B.-K.K., H.-S.K.).

Circulation
|November 7, 2022
PubMed
概括

与阿司匹林相比,通过皮肤输出支架进行冠状动脉干预后长期单一治疗可显著减少主要不良事件. 这项扩大后续调查证实了克洛皮多格勒的

关键词:
通过皮肤进行冠状动脉干预血小板聚合抑制剂治疗结果

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

相关实验视频

Last Updated: Aug 22, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

科学领域:

  • 心脏病学
  • 药理学
  • 临床试验

背景情况:

  • 使用药物释放支架 (DES) 进行皮肤冠状动脉干预 (PCI) 后的抗血小板单一治疗的长期结果尚不完全理解.
  • 这项HOST- EXAM扩展研究提供了对抗血小板单一治疗策略的关键后续数据.

研究的目的:

  • 评估克洛皮多格勒单疗与阿司匹林单疗的长期疗效和安全性.
  • 在克洛皮多格勒和阿司匹林单一治疗组之间比较综合净临床结果,血栓事件和出血事件.

主要方法:

  • 在12±6个月的双重抗血小板治疗中,有5348名DES- PCI患者被随机分配到克洛皮多格勒或阿司匹林单一治疗中.
  • 主要终点:死亡,心肌梗塞,中风,ACS再入院和BARC≥3出血的综合结果.
  • 二次终点:在延长的随访期内分析的血栓和出血事件.

主要成果:

  • 在中位数为5. 8年的时间里,克洛皮多格雷尔单独治疗的初级复合终点率显著降低 (12. 8% vs 16. 9%;HR 0. 74,P< 0. 001).
  • 用克洛皮多格雷尔观察到二次血栓形成的风险降低 (HR 0.66,P< 0.001) 和出血的终点 (HR 0.74,P=0.016).
  • 两组之间无显著的死亡率差异 (P=0. 742);克洛皮多格勒的长期益处是一致的.

结论:

  • 与阿司匹林单一治疗相比,克洛皮多格雷尔单一治疗在特定的PCI患者中具有更好的长期临床结果.
  • 这些发现支持单独使用克洛皮多格勒作为一种潜在的更有效的策略来减少缺血事件,同时管理PCI后的出血风险.